Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Doolan

Podiatrist, Foot & Ankle Surgery New York, NY Doctor of Podiatric Medicine

NPI 1073540480 CMS profile 93468

525 E 68Th St, New York, NY 10065

Open in the dashboard

General payments

$86,740

445 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Doolan of New York, NY is reported in the CMS Open Payments database as having received $86,740 across 445 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,637 118
2024 General $11,999 88
2023 General $13,189 69
2022 General $10,344 58
2021 General $6,248 38
2020 General $5,220 30
2019 General $18,104 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Doolan
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to John Doolan were reported at $21,637. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year John Doolan Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $18,104 $389 $118–$1,406 $163
2020 $5,220 $191 $62–$691 $114
2021 $6,248 $329 $104–$1,341 $132
2022 $10,344 $419 $125–$1,611 $149
2023 $13,189 $377 $128–$1,164 $160
2024 $11,999 $394 $134–$1,168 $164
2025 $21,637 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organogenesis Inc. $27,908 79 payments
  2. Royal Biologics $16,120 39 payments
  3. PolyNovo North America LLC $12,193 72 payments
  4. Gramercy Extremity Orthopedics LLC $7,698 17 payments
  5. Musculoskeletal Transplant Foundation Inc. $3,089 16 payments
  6. Stryker Corporation $2,042 17 payments
  7. Acera Surgical, Inc. $1,781 13 payments
  8. Trilliant Surgical LLC. $1,640 3 payments
  9. Smith+Nephew, Inc. $1,421 53 payments
  10. Gotham Surgical Solutions & Devices, Inc. $1,200 1 payment
  11. Other $11,648 135 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $32,355 379 payments
  2. Consulting Fee $22,187 17 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21,363 20 payments
  4. Travel and Lodging $6,616 20 payments
  5. Honoraria $2,300 2 payments
  6. Education $1,240 2 payments
  7. Royalty or License $679 5 payments
Products named General payments · program years 2019–2025
  1. NOVOSORB BTM $11,781 69 payments
  2. Puraply $11,486 32 payments
  3. PURAPLY WOUND MATRIX $7,238 14 payments
  4. Fibrinet $6,883 12 payments
  5. APLIGRAF Wound Care $6,357 13 payments
  6. MaxxCell $6,100 4 payments
  7. AmnioMaxx $5,792 6 payments
  8. Apligraf Podiatry $3,983 8 payments
  9. Puraply/Affinity/NuTech $3,983 8 payments
  10. Dermagraft $3,983 8 payments
  11. Other $45,547 378 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

212

Median for Podiatry: 160

Drug cost

$10,771

Median for Podiatry: $2,368

Branded share of claims

11.3%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 24 $8,260
Celecoxib Generic 12 $618
Ammonium Lactate Generic 20 $555
Terbinafine Hcl Generic 60 $452
Ketoconazole Generic 37 $429
Gabapentin Generic 11 $190
Diclofenac Sodium Generic 18 $156
Mupirocin Generic 11 $57
Meloxicam Generic 19 $55

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$296,072

Of which drugs: $162,813

Medicare patients

397

Average age 75

Services billed

3,178

225 women, 172 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 65%
Diabetes 42%
Ischemic heart disease 37%
Chronic kidney disease 30%
Depression 28%
Osteoporosis 25%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 49 140 $104
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 52 318 $27

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
  • AbbVie, Inc. $43
$43 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $22
$22 — —
TEFLARO
  • AbbVie, Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

445 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record